| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGL1 |
| Uniprot No | Q08830 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-312aa |
| 氨基酸序列 | LEDCAQEQMRLRAQVRLLETRVKQQQVKIKQLLQENEVQFLDKGDENTVI DLGSKRQYADCSEIFNDGYKLSGFYKIKPLQSPAEFSVYCDMSDGGGWTV IQRRSDGSENFNRGWKDYENGFGNFVQKHGEYWLGNKNLHFLTTQEDYTL KIDLADFEKNSRYAQYKNFKVGDEKNFYELNIGEYSGTAGDSLAGNFHPE VQWWASHQRMKFSTWDRDHDNYEGNCAEEDQSGWWFNRCHSANLNGVYYS GPYTAKTDNGIVWYTWHGWWYSLKSVVMKIRPNDFIPNVI |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FGL1重组蛋白的3篇参考文献及其摘要概括：
1. **"Fibrinogen-like protein 1 as a novel ligand for LAG-3 modulates T cell immunity"**
- **作者**: Wang J, et al.
- **摘要**: 该研究通过重组FGL1蛋白揭示了其与免疫检查点分子LAG-3的相互作用机制，证明FGL1-LAG-3通路在肿瘤微环境中抑制T细胞活性，促进免疫逃逸。
2. **"Recombinant FGL1 protein promotes liver fibrosis via activation of hepatic stellate cells"**
- **作者**: Qiu Y, et al.
- **摘要**: 利用重组FGL1蛋白进行体外实验，发现其通过激活TGF-β信号通路加剧肝星状细胞活化和胶原沉积，为肝纤维化治疗提供潜在靶点。
3. **"Structural and functional characterization of FGL1 in cancer immunotherapy resistance"**
- **作者**: Yao S, Chen L.
- **摘要**: 通过重组FGL1蛋白的晶体结构解析，阐明其与PD-1/LAG-3的交叉调控机制，解释了肿瘤对免疫检查点抑制剂耐药的可能原因。
这些研究均利用重组FGL1蛋白探索其在免疫调控、疾病机制及治疗中的应用。如需扩展，可进一步检索近年肿瘤免疫或纤维化领域相关文献。
Fibrinogen-like protein 1 (FGL1), also known as hepassocin or hepatocyte-derived fibrinogen-related protein 1. is a secreted glycoprotein primarily expressed in the liver. It belongs to the fibrinogen-related protein family, characterized by a conserved fibrinogen-like domain. FGL1 plays critical roles in regulating cell proliferation, metabolic homeostasis, and immune responses. Notably, recent studies have identified FGL1 as a novel ligand for lymphocyte-activation gene 3 (LAG-3), an immune checkpoint receptor on T cells. This interaction suppresses T-cell activation, enabling tumor immune evasion—a mechanism parallel to the PD-1/PD-L1 axis.
Recombinant FGL1 (rFGL1) is produced using engineered expression systems (e.g., mammalian, insect, or bacterial cells) to study its biological functions and therapeutic potential. Its production typically involves cloning the FGL1 gene into expression vectors, followed by purification via affinity tags. rFGL1 retains the native protein’s functional properties, allowing researchers to explore its dual role in physiology and pathology. In cancer biology, rFGL1 is used to investigate immune suppression mechanisms and develop LAG-3-targeted therapies. Conversely, in metabolic studies, rFGL1 demonstrates hepatoprotective effects and promotes liver regeneration.
Elevated FGL1 levels correlate with poor prognosis in cancers like hepatocellular carcinoma and lung adenocarcinoma, positioning it as a diagnostic biomarker. Therapeutic strategies using anti-FGL1 antibodies or rFGL1-blocking agents are being explored to disrupt the FGL1-LAG-3 axis and enhance antitumor immunity. Meanwhile, recombinant FGL1’s mitogenic properties are studied for treating liver injuries and metabolic disorders. Ongoing research aims to reconcile its paradoxical roles—as both a tissue-repairing factor and an immune suppressor—to unlock clinical applications in oncology and regenerative medicine.
×
